Previous close | 52.92 |
Open | 56.10 |
Bid | 52.98 x 300 |
Ask | 53.38 x 100 |
Day's range | 51.30 - 56.10 |
52-week range | 14.19 - 72.29 |
Volume | |
Avg. volume | 688,493 |
Market cap | 3.11B |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Key Insights Institutions' substantial holdings in Apogee Therapeutics implies that they have significant influence...
Apogee (APGE) surges 95.6% in a month after reporting positive interim results from its phase I study for APG777 to treat AD. The company plans to initiate a phase II study for the same indication.
Last week, Apogee Therapeutics, Inc. ( NASDAQ:APGE ) insiders, who had purchased shares in the previous 12 months were...